Second-line atezolizumab plus cabozantinib did not generate a clinical benefit over standard-of-care docetaxel in patients with metastatic non–small cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy.
At the 2023 European Lung Cancer Congress, results from the recent findings of the CONTACT-01 trial showed no benefit for patients with metastatic non–small cell lung cancer on the combination of atezolizumab and cabozantinib compared with the standard of care.
Das Historische Museum versucht einen Neuanfang bzbasel.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bzbasel.ch Daily Mail and Mail on Sunday newspapers.
ياسر عبيدو يكتب: الرابح طالبان أم أمريكا elbalad.news - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from elbalad.news Daily Mail and Mail on Sunday newspapers.